NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102

This notice is provided pursuant to the requirements of Section 4.9 of National Instrument 51-102 *Continuous Disclosure Obligations*.

Item 1. Names of the Parties to the Transaction

The following corporate entities were parties to the transaction:

(a) Aurora Cannabis Inc. ("**Aurora**"), a company incorporated under the laws of the Province of British Columbia, Canada; and

(b) CanniMed Therapeutics Inc. ("**CanniMed**"), a company incorporated under the laws of Canada.

Item 2. Description of the Transaction

On May 1, 2018, Aurora completed the acquisition of all of the remaining outstanding shares of CanniMed (the "**CanniMed Shares**"). The CanniMed Shares were acquired pursuant to the compulsory acquisition procedures set out in Part XVII of the *Business Corporations Act* (Canada) and consist of those CanniMed Shares that were not tendered to Aurora's offer to acquire all of the CanniMed Shares (the "**Offer**") set out in Aurora's offer to purchase and accompanying takeover bid circular dated November 24, 2017, as amended by the notice of change dated January 12, 2018, the notice of variation dated February 5, 2018 and the notice of variation and extension dated March 9, 2018 (collectively, the "**Offer Documents**"). The Offer expired at 11:59 p.m. (Pacific Time) on March 24, 2018. At the conclusion of the Offer, Aurora had taken up approximately 23.5 million CanniMed Shares, representing 93.1% of the outstanding CanniMed Shares. Aurora issued approximately 69.3 million common shares and paid approximately $134 million for the CanniMed Shares taken-up. At the conclusion of the offer, Aurora owned approximately 95.9% of the outstanding CanniMed Shares (including CanniMed Shares acquired in market purchases during the period the Offer was open for acceptance).

The approximately 1.2 million CanniMed Shares remaining were acquired for consideration of approximately 3.4 million Aurora shares and $1.7 million in cash. The CanniMed Shares were de-listed from the Toronto Stock Exchange ("TSX") as at the close of business on May 1, 2018.

The Offer is more particularly described in the Offer Documents, sent to holders of CanniMed Shares and options in connection with the Offer. Copies of the Offer

Documents are available under CanniMed's profile on SEDAR at www.sedar.com.

Item 3. Effective Date of the Transaction

The compulsory acquisition was effective on May 1, 2018.

Item 4. Name of Each Party, if any, that Ceased to be a Reporting Issuer After the Transaction and of Each Continuing Entity

CanniMed ceased to be a reporting issuer in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland pursuant to the order of the Financial and Consumer Affairs Authority of Saskatchewan on dated May 31, 2018, which also evidences the decision of the Ontario Securities Commission.

Aurora remains a reporting issuer in all of the provinces of Canada.

Item 5. Date of the Reporting Issuer's First Financial Year-End After the Transaction

Not applicable.

Item 6. Periods, Including the Comparative Periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year After the Transaction

Not applicable.

Item 7. Documents Filed Under National Instrument 51-102

Not applicable.

DATED the 1st day of June, 2018.

CANNIMED THERAPEUTICS INC.

Per: "*Andre Jerome*"
Name: Andre Jerome
Title: Chief Executive Officer